European Federation for Medicinal Chemistry in partnership with MedChemComm

Dear Colleagues,

MedChemComm, the official journal of the European Federation for Medicinal Chemistry, is entering now into its third year. After a successful launch at the 21st International Symposium on Medicinal Chemistry (EFMC–ISMC) in Brussels in 2010, the journal continues to grow the high quality content that it has published, with a strong contribution from European authors. In 2011 MedChemComm has published a web theme consisting of articles provided by speakers at the 2010 ISMC meeting in Brussels. For 2012 we are currently working on a web theme on Epigenetics and I would like to thank Mark Bunnage and Rasmus Claussen for taking the lead on this initiative. These web themes are a great example of the productive partnership between MedChemComm and the Royal Society of Chemistry and the EFMC. It is the ambition of both the Royal Society of Chemistry and the EFMC to develop MedChemComm into the leading medicinal chemistry journal. With the Royal Society of Chemistry we are delighted to have a partner, whose journals are among the highest ranked ones in their disciplines, which combine top quality publishing service and a very author-friendly copyright policy. RSC is the partner of choice for EFMC with its strong commitment to high scientific standards.

EFMC is organizing or co-organizing a series of scientific meetings during the year 2012. For 2012, the main event will be the XXIInd International Symposium on Medicinal Chemistry (ISMC), organized by our two German Member Societies in Berlin, September 2–6. As for previous editions, the meeting will cover all major therapeutic areas, new technologies and latest hot topics. Special emphasis will be put on case studies and first time disclosures. The registration is already open and I would like to encourage you to register for this premier medicinal chemistry event of 2012.

On occasion of the XXIInd ISMC meeting, the three EFMC Awards will be conferred. These are the Nauta Award for Pharmacochemistry, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute – Overton and Meyer Award for New Technologies in Drug Discovery. In addition, there will be EFMC prizes to acknowledge scientific achievements of a young medicinal chemist from Industry and one from Academia. The call for applications for the awards and the prizes will be open until end of January, and I encourage you to visit our web-page http://www.efmc.info for further information and to submit an application.

Among other major events coming up in 2012 under the auspices of EFMC I wish to highlight the 30th Noordwijkerhout–Camerino–Cyprus Symposium, which will take place on May 13–17 in Amsterdam (Netherlands), the 21st Italian National Meeting in Medicinal Chemistry to be held in Palermo (Italy) on July 17–21, the 19th EuroQSAR – Knowledge Enabled Ligand Design which will take place on August 26–31 in Vienna (Austria), and the EFMC sponsored session at the 4th EuCheMS Chemistry Congress in Prague (Czech Republic) on August 26–30.

The Speakers at these events will be asked to publish their work in MedChemComm and I would like to encourage you, as well, to submit your manuscripts to MedChemComm to share your results with the medicinal chemistry community.

Uli Stilz

President EFMC

---